Lung cancer cells with RICTOR amplification showed increased sensitivity to mTORC1/2 inhibitors, whereas silencing RICTOR rendered RICTOR-amplified cells markedly more resistant to mTORC1/2 inhibitors, demonstrating that RICTOR was the target in those cells [25]. This evidence concerns the gene RICTOR and lung cancer.